The abstract is read at the publisher; the summary is JClub's.
Crosslinked ionizable lipid C12-2aN LNPs reprogram dendritic cell metabolism to enhance mRNA vaccination, yielding stronger SARS-CoV-2 pseudovirus neutralization and improved OVA cancer survival versus control LNPs.
- Why it matters: Immune-cell metabolic control is a promising lever for shaping vaccine responses, but integrating delivery with targeted metabolic reprogramming in dendritic cells remains challenging.
- What they did: The authors synthesized an imidoester-conjugated, crosslinked ionizable lipid (C12-2aN) and used it in LNPs to promote endosomal escape and stimulate glycolysis via mTORC2 pathway activation.
- The result: In SARS-CoV-2 and OVA cancer vaccine models, C12-2aN LNPs improved neutralization and survival and also reduced off-target delivery and immunogenicity compared with control LNPs and FDA-approved LNPs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.